CLINICAL_TRIALS
trial_result
· 2021-06-01
Clinical Trial Update: 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension) [Phase 3]
Summary
A 2-year extension study (STEADFAST Extension) of Azeliragon in Alzheimer's disease was terminated; results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: vTv Therapeutics | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2021-06-01